Finasteride Tablet, Film Coated
Product Images NDC 68071-3417

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-3417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3417 3)

The text is a label of NuCare Pharmaceuticals, Inc's Finasteride 5mg. It is a prescription medicine that is used to treat hair loss in men. The label provides the information on the product's lot and serial number, and the manufacturer's and distributor's National Drug Code (NDC). It is advised to store the medicine at the controlled temperature and to keep it away from children's reach. The label also warns patients to seek medical advice if they experience any side effects and to report them to the FDA.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

This appears to be a table or figure showing the Mean Change from Baseline with 1 Standard Error (SE) in Symptom Score in two long term efficacy and safety study for a comparison between a placebo and Finasteride. However, without additional context or information, it is difficult to draw any more conclusions or provide a more specific description.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

The text describes a figure (Figure 2) showing the percent of patients who have surgery for BPH (benign prostatic hyperplasia), including TURP (transurethral resection of the prostate). The graph compares the percentage of patients who underwent surgery while taking finasteride versus those taking a placebo. The observation time is measured in months. The number of events and at-risk patients per year are also given for each group.*

FDA Label Image

Figure3 (Finasteride Fig3)

This is a figure containing a graph that shows the percentage of patients who developed acute urinary retention (whether spontaneous or precipitated), achieved with the use of Finasteride and placebo. The graph is plotted over an observation time of months, ranging from 0 to 24. The Finasteride group displays a lower percentage of patients who develop the condition when compared to the Placebo group. The figure also presents some data on the number of events and individuals at risk for both groups.*

FDA Label Image

Figure4 (Finasteride Fig4)

The text describes the measurement of prostate volume in a long-term study of efficacy and safety. The results are presented graphically in Figure 4, showing the mean percent change from baseline over 4 years (baseline and year 1-3). The study compares the effects of a placebo and finasteride on prostate volume. The sample size for each group is also provided.*

FDA Label Image

Figure5 (Finasteride Fig5)

FDA Label Image

Chemical Structure (Finasteride Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.